Archives
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-11
- 2018-10
- 2018-07
-
In the present study promoting bile acid
2020-06-22

In the present study, promoting bile Prochlorperazine synthesis synthesis by activating EP4 receptors was shown to exert protection against hepatic steatosis. This finding may be relevant for treatment of non-alcoholic fatty liver disease, a major cause of liver disease and prominent indication for
-
Importantly MPO is not only
2020-06-22

Importantly, MPO is not only a marker of cardiovascular disease but also emerges as a critical mediator of vascular inflammatory disease: Liberated MPO binds to the endothelium in a leukocyte-independent manner, is subsequently taken up by the endothelium and transcytoses and accumulates in the sube
-
br Chain specific ubiquitin probes The
2020-06-22

Chain specific ubiquitin probes The conventional way of assessing linkage specificity is by measuring turnover rates of different diubiquitin molecules as substrates. Although this method has been applied successfully in several studies [7••, 8] it is limited to isolated DUBs, whereas linkage spe
-
The possibility of harm with DPP
2020-06-22

The possibility of harm with DPP-4 inhibitors in patients with clinically overt heart failure has been recently highlighted by the results of the VIVIDD (Vildagliptin in Ventricular Dysfunction Diabetes) trial (68), the only trial to date that has been designed to evaluate the effects of a DPP-4 inh
-
br Dienogest DNG Dienogest is a nortestosterone derivative w
2020-06-20

Dienogest (DNG) Dienogest is a 19-nortestosterone derivative with two special structural changes [Fig. 1a]: [a] At the cabon-17 position there is a cyanomethyl group instead of an ethinyl group; [b] A double bond is present between carbons 9 and 10. DNG is the only progestogen that combines prope
-
When a hour delay period was implemented for the
2020-06-20

When a 6-hour delay fak inhibitor was implemented for the WRAM, neither of the E2-treated groups (E2-only and E2 + Levo) differed in WMC errors between the postdelay trials and the baseline trials. This suggests that exogenous E2 treatment protected from a delay-induced impairment in performance on
-
ERR induces the expression of P c in MA cells
2020-06-20

ERRγ induces the expression of P450c17 in MA-10 cells and in mouse primary Leydig cells (Fig. 2). Deletion mutant analysis of putative ERRγ-binding sites in the P450c17 promoter suggested that only the proximal third site located between −269 bp and −136 bp within the P450c17 promoter is functional
-
Amoxapine One possible pitfall of using EPAC activators in t
2020-06-20

One possible pitfall of using EPAC2 activators in the treatment of T2DM is their potential to increase glucagon levels. As discussed previously, although the ability of EPAC2 to increase glucagon expression and production is controversial, several studies show that this protein increases Gcg mRNA le
-
The N terminal amino acid sequence was
2020-06-20

The N-terminal amino MDL 28170 sequence was made for STH2. This sequence showed high similarity (100%) with to trypsin-like found in the human airway classified as serine proteinase that also belongs to peptidase family SI and related also with chymotrypsin-like enzymes (Yasuoka et al., 1997). The
-
br Mechanisms of acquired resistance to
2020-06-20

Mechanisms of acquired resistance to 1st and 2nd generation EGFR inhibitors After treatment with first or second generation EGFR TKIs, virtually all patients after approximately 12 months develop acquired resistance (AR). Different mechanisms of AR to EGFR TKIs have been reported to date and may
-
Although both DNA DSBs and DNA
2020-06-20

Although both DNA DSBs and DNA-PK activity increase with aging in skeletal muscle (Figure 1), we cannot conclude that aging-associated increase in DNA-PK activity is solely mediated by chromosomal breaks, as DNA-PK is also activated independently of chromosomal breaks by ROS (Li et al., 2014), which
-
CFSs are recognized as a driver
2020-06-20

CFSs are recognized as a driver of genome instability in human cells and are hotspots for deletions or translocations in cancers (Richards, 2001). The generally accepted model for their expression is that the CFS locus shows a delay in chromatin condensation in early mitosis caused by the persistenc
-
Other factors also contribute to replication fork progressio
2020-06-20

Other factors also contribute to replication fork progression in DNA damage conditions. For instance, the cullin Rtt101 has a role in fork movement through alkylated DNA, probably associated to a damage tolerance mechanism [52], and TORC signaling is also important for fork progression in response t
-
Cysteine protease inhibitors representing several
2020-06-20

Cysteine protease inhibitors representing several chemical scaffold types are effective in halting parasite replication without toxicity to the host (Renslo and McKerrow, 2006). A vinyl sulfone cysteine protease inhibitor, K11777, is completing final Good Laboratory Practice (GLP) preclinical tests
-
Apparently no study has been undertaken on alterations in ch
2020-06-19

Apparently, no study has been undertaken on alterations in cholinesterase activity and its correlation with neurological disorders in clinical case of trypanosomosis in buffaloes. Therefore, the present study was undertaken to evaluate the alterations in cholinesterase activity in clinical cases of
16197 records 834/1080 page Previous Next First page 上5页 831832833834835 下5页 Last page